A Phase1b/2, Multicenter, Randomized, Open-label Study to Evaluate the Efficacy and Safety of GSK5764227 Alone and in Combination in Participants With Previously Treated Advanced Unresectable or Metastatic Gastrointestinal Solid Tumors
Latest Information Update: 16 Apr 2025
At a glance
- Drugs HS-20093 (Primary)
- Indications Colorectal cancer; Gastric cancer
- Focus Therapeutic Use
- Sponsors GSK
Most Recent Events
- 19 Mar 2025 Status changed from planning to not yet recruiting.
- 23 Aug 2024 New trial record
- 20 Aug 2024 According to a GSK media release, company plans to begin global phase 1/2 trials in 2H 2024 to support a registrational pathway for GSK'227